drugset / Trial / NCT03369002
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of seladelpar following administration of a single oral dose in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal hepatic function.
Timeline
- Start
- 2017-11-27
- Primary completion
- 2018-05-15
- Completion
- 2018-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seladelpar | Small molecule | 10 mg | Oral |
Indications
No indication recorded.